Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
1.300
+0.020 (1.56%)
Jun 27, 2025, 4:00 PM - Market closed
Evogene Revenue
Evogene had revenue of $2.44M in the quarter ending March 31, 2025, a decrease of -41.67%. This brings the company's revenue in the last twelve months to $6.77M, down -26.38% year-over-year. In the year 2024, Evogene had annual revenue of $8.51M with 50.90% growth.
Revenue (ttm)
$6.77M
Revenue Growth
-26.38%
P/S Ratio
2.00
Revenue / Employee
$57,821
Employees
117
Market Cap
13.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.51M | 2.87M | 50.90% |
| Dec 31, 2023 | 5.64M | 3.97M | 236.72% |
| Dec 31, 2022 | 1.68M | 745.00K | 80.11% |
| Dec 31, 2021 | 930.00K | -110.00K | -10.58% |
| Dec 31, 2020 | 1.04M | 287.00K | 38.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
EVGN News
- 18 days ago - Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud - PRNewsWire
- 5 weeks ago - Evogene Ltd. (EVGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Evogene Reports First Quarter 2025 Financial Results - PRNewsWire
- 7 weeks ago - Evogene Schedules First Quarter 2025 Financial Results Release - PRNewsWire
- 2 months ago - ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio - PRNewsWire
- 4 months ago - Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Evogene Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 4 months ago - Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025 - PRNewsWire